|
|
Trans Am Ophthalmol Soc. 1998; 96: 721–752. | PMCID: PMC1298413 |
Tumor vascularity and hematogenous metastasis in experimental murine intraocular melanoma. H E Grossniklaus Department of Ophthalmology, Emory University School of Medicine, Atlanta, Georgia, USA. Abstract PURPOSE: The purpose of this study is to test the hypothesis that primary tumor vascularity in a murine model of intraocular melanoma positively correlates with the development and hematogenous spread of metastasis. METHODS: Forty 12-week-old C57BL6 mice were inoculated in either the anterior chamber (AC) or posterior compartment (PC) of 1 eye with 5 x 10(5) cells/microL of Queens tissue culture melanoma cells. The inoculated eye was enucleated at 2 weeks; the mice were sacrificed at 4 weeks postinoculation, and necropsies were performed. The enucleated eyes were examined for histologic and ultrastructural features, including relationship of tumor cells to tumor vascular channels, vascular pattern, and mean vascular density. RESULTS: Melanoma grew and was confined to the eye in 12 of 20 AC eyes and 10 of 20 PC eyes. Histologic and electron microscopic examination showed tumor invasion into vascular channels. Five of 12 AC tumors (42%) and 8 of 10 PC tumors (80%) metastasized. All of the AC tumors, but none of the PC tumors, that distantly metastasized also metastasized to ipsilateral cervical lymph nodes (P = .00535). There was no statistically significant difference of vascular pattern between the melanomas that did and did not metastasize to lungs in the PC group (P = .24), although there was a significant difference in the AC group (P = .02). Tumors with high-grade vascular patterns were more likely to metastasize than tumors with low-grade vascular patterns in the AC group. The mean vascular density positively correlated with the presence and number of metastases in both groups (P = .0000 and P < .001, respectively). There was no statistically significant difference of vascular pattern and mean vascular density for AC versus PC melanoma (P = .97). CONCLUSIONS: The rate of metastasis in this murine intraocular melanoma model positively correlates with primary tumor vascularity. The melanoma metastasizes via invasion of tumor vascular channels. AC melanoma also metastasizes through regional lymphatics. Full text Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (6.1M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References. Images in this article Click on the image to see a larger version. These references are in PubMed. This may not be the complete list of references from this article. - McLean IW, Zimmerman LE, Evans RM. Reappraisal of Callender's spindle a type of malignant melanoma of choroid and ciliary body. Am J Ophthalmol. 1978 Oct;86(4):557–564. [PubMed]
- FLOCKS M, GERENDE JH, ZIMMERMAN LE. The size and shape of malignant melanomas of the choroid and ciliary body in relation to prognosis and histologic characteristics; a statistical study of 210 tumors. Trans Am Acad Ophthalmol Otolaryngol. 1955 NovâDec;59(6):740–758. [PubMed]
- Gamel JW, McLean IW. Computerized histopathologic assessment of malignant potential. II. A practical method for predicting survival following enucleation for uveal melanoma. Cancer. 1983 Sep 15;52(6):1032–1038. [PubMed]
- Gamel JW, McLean IW, Greenberg RA, Zimmerman LE, Lichtenstein SJ. Computerized histologic assessment of malignant potential: a method for determining the prognosis of uveal melanomas. Hum Pathol. 1982 Oct;13(10):893–897. [PubMed]
- McCurdy J, Gamel J, McLean I. A simple, efficient, and reproducible method for estimating the malignant potential of uveal melanoma from routine H & E slides. Pathol Res Pract. 1991 Dec;187(8):1025–1027. [PubMed]
- Gamel JW, McLean IW. Modern developments in histopathologic assessment of uveal melanomas. Ophthalmology. 1984 Jun;91(6):679–684. [PubMed]
- Gamel JW, McLean IW. Computerized histopathologic assessment of malignant potential. III. Refinements of measurement and data analysis. Anal Quant Cytol. 1984 Mar;6(1):37–44. [PubMed]
- McLean MJ, Foster WD, Zimmerman LE. Prognostic factors in small malignant melanomas of choroid and ciliary body. Arch Ophthalmol. 1977 Jan;95(1):48–58. [PubMed]
- de la Cruz PO, Jr, Specht CS, McLean IW. Lymphocytic infiltration in uveal malignant melanoma. Cancer. 1990 Jan 1;65(1):112–115. [PubMed]
- Vit VV. Prognosticheskoe znachenie morfologicheskikh priznakov immunnogo otveta pri uveal'nykh melanoblastomakh razlichnogo kletochnogo tipa. Arkh Patol. 1983;45(7):25–30. [PubMed]
- Gamel JW, McCurdy JB, McLean IW. A comparison of prognostic covariates for uveal melanoma. Invest Ophthalmol Vis Sci. 1992 May;33(6):1919–1922. [PubMed]
- Folberg R, Pe'er J, Gruman LM, Woolson RF, Jeng G, Montague PR, Moninger TO, Yi H, Moore KC. The morphologic characteristics of tumor blood vessels as a marker of tumor progression in primary human uveal melanoma: a matched case-control study. Hum Pathol. 1992 Nov;23(11):1298–1305. [PubMed]
- Folberg R, Rummelt V, Parys-Van Ginderdeuren R, Hwang T, Woolson RF, Pe'er J, Gruman LM. The prognostic value of tumor blood vessel morphology in primary uveal melanoma. Ophthalmology. 1993 Sep;100(9):1389–1398. [PubMed]
- Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred EN, Moore DH, Meli S, Gasparini G. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst. 1992 Dec 16;84(24):1875–1887. [PubMed]
- Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol. 1993 Aug;143(2):401–409. [PubMed]
- Foss AJ, Alexander RA, Jefferies LW, Hungerford JL, Harris AL, Lightman S. Microvessel count predicts survival in uveal melanoma. Cancer Res. 1996 Jul 1;56(13):2900–2903. [PubMed]
- Zimmerman LE, McLean IW. Montgomery Lecture, 1975. Changing concepts of the prognosis and management of small malignant melanomas of the choroid. Trans Ophthalmol Soc U K. 1975;95(4):487–494. [PubMed]
- Char DH, Crawford JB, Irvine AR, Hogan MJ, Howes EL., Jr Correlation between degree of malignancy and the radioactive phosphorus uptake test in ocular melanomas. Am J Ophthalmol. 1976 Jan;81(1):71–75. [PubMed]
- Gamel JW, McLean IW. Quantitative analysis of the Callender classification of uveal melanoma cells. Arch Ophthalmol. 1977 Apr;95(4):686–691. [PubMed]
- Gamel JW, Gleason J, Williams H, Greenberg R. Reproducibility of nucleolar measurements in human intraocular melanoma cells on standard histologic microslides. Anal Quant Cytol Histol. 1985 Sep;7(3):174–177. [PubMed]
- Pe'er J, Rummelt V, Mawn L, Hwang T, Woolson RF, Folberg R. Mean of the ten largest nucleoli, microcirculation architecture, and prognosis of ciliochoroidal melanomas. Ophthalmology. 1994 Jul;101(7):1227–1235. [PubMed]
- Gamel JW, McLean IW, McCurdy JB. Biologic distinctions between cure and time to death in 2892 patients with intraocular melanoma. Cancer. 1993 Apr 1;71(7):2299–2305. [PubMed]
- Mehaffey MG, Folberg R, Meyer M, Bentler SE, Hwang T, Woolson R, Moore KC. Relative importance of quantifying area and vascular patterns in uveal melanomas. Am J Ophthalmol. 1997 Jun;123(6):798–809. [PubMed]
- Folberg R, Mehaffey M, Gardner LM, Meyer M, Rummelt V, Pe'er J. The microcirculation of choroidal and ciliary body melanomas. Eye (Lond). 1997;11(Pt 2):227–238. [PubMed]
- Brown D, Boniuk M, Font RL. Diffuse malignant melanoma of iris with metastases. Surv Ophthalmol. 1990 Mar–Apr;34(5):357–364. [PubMed]
- Jakobiec FA, Silbert G. Are most iris "melanomas' really nevi? A clinicopathologic study of 189 lesions. Arch Ophthalmol. 1981 Dec;99(12):2117–2132. [PubMed]
- Grossniklaus HE, Oakman JH, Cohen C, Calhoun FP, Jr, DeRose PB, Drews-Botsch C. Histopathology, morphometry, and nuclear DNA content of iris melanocytic lesions. Invest Ophthalmol Vis Sci. 1995 Mar;36(3):745–750. [PubMed]
- RONES B, ZIMMERMAN LE. The prognosis of primary tumors of the iris treated by iridectomy. AMA Arch Ophthalmol. 1958 Aug;60(2):193–205. [PubMed]
- Zakka KA, Foos RY, Sulit H. Metastatic tapioca iris melanoma. Br J Ophthalmol. 1979 Nov;63(11):744–749. [PubMed]
- Sunba MS, Rahi AH, Morgan G. Tumors of the anterior uvea. I. Metastasizing malignant melanoma of the iris. Arch Ophthalmol. 1980 Jan;98(1):82–85. [PubMed]
- Jiang LQ, Jorquera M, Streilein JW. Subretinal space and vitreous cavity as immunologically privileged sites for retinal allografts. Invest Ophthalmol Vis Sci. 1993 Nov;34(12):3347–3354. [PubMed]
- Folkman J. The vascularization of tumors. Sci Am. 1976 May;234(5):58-64–70-3. [PubMed]
- Tapper D, Langer R, Bellows AR, Folkman J. Angiogenesis capacity as a diagnostic marker for human eye tumors. Surgery. 1979 Jul;86(1):36–40. [PubMed]
- Muthukkaruppan VR, Kubai L, Auerbach R. Tumor-induced neovascularization in the mouse eye. J Natl Cancer Inst. 1982 Sep;69(3):699–708. [PubMed]
- Risau W. Angiogenesis and endothelial cell function. Arzneimittelforschung. 1994 Mar;44(3A):416–417. [PubMed]
- Miller JW, Adamis AP, Shima DT, D'Amore PA, Moulton RS, O'Reilly MS, Folkman J, Dvorak HF, Brown LF, Berse B, et al. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol. 1994 Sep;145(3):574–584. [PubMed]
- Senger DR, Van de Water L, Brown LF, Nagy JA, Yeo KT, Yeo TK, Berse B, Jackman RW, Dvorak AM, Dvorak HF. Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev. 1993 Sep;12(3-4):303–324. [PubMed]
- Liu B, Earl HM, Baban D, Shoaibi M, Fabra A, Kerr DJ, Seymour LW. Melanoma cell lines express VEGF receptor KDR and respond to exogenously added VEGF. Biochem Biophys Res Commun. 1995 Dec 26;217(3):721–727. [PubMed]
- Claffey KP, Brown LF, del Aguila LF, Tognazzi K, Yeo KT, Manseau EJ, Dvorak HF. Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis. Cancer Res. 1996 Jan 1;56(1):172–181. [PubMed]
- Danø K, Andreasen PA, Grøndahl-Hansen J, Kristensen P, Nielsen LS, Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res. 1985;44:139–266. [PubMed]
- Meissauer A, Kramer MD, Hofmann M, Erkell LJ, Jacob E, Schirrmacher V, Brunner G. Urokinase-type and tissue-type plasminogen activators are essential for in vitro invasion of human melanoma cells. Exp Cell Res. 1991 Feb;192(2):453–459. [PubMed]
- Vinores SA, Küchle M, Mahlow J, Chiu C, Green WR, Campochiaro PA. Blood-ocular barrier breakdown in eyes with ocular melanoma. A potential role for vascular endothelial growth factor/vascular permeability factor. Am J Pathol. 1995 Nov;147(5):1289–1297. [PubMed]
- Kvanta A, Steen B, Seregard S. Expression of vascular endothelial growth factor (VEGF) in retinoblastoma but not in posterior uveal melanoma. Exp Eye Res. 1996 Nov;63(5):511–518. [PubMed]
- ten Berge PJ, Danen EH, van Muijen GN, Jager MJ, Ruiter DJ. Integrin expression in uveal melanoma differs from cutaneous melanoma. Invest Ophthalmol Vis Sci. 1993 Dec;34(13):3635–3640. [PubMed]
- Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T, Klier G, Cheresh DA. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell. 1994 Dec 30;79(7):1157–1164. [PubMed]
- Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995 Jan;1(1):27–31. [PubMed]
- Folkman J. Angiogenesis and breast cancer. J Clin Oncol. 1994 Mar;12(3):441–443. [PubMed]
- Zhang Y, Deng Y, Luther T, Müller M, Ziegler R, Waldherr R, Stern DM, Nawroth PP. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J Clin Invest. 1994 Sep;94(3):1320–1327. [PubMed]
- Contrino J, Hair GA, Schmeizl MA, Rickles FR, Kreutzer DL. In situ characterization of antigenic and functional tissue factor expression in human tumors utilizing monoclonal antibodies and recombinant factor VIIa as probes. Am J Pathol. 1994 Dec;145(6):1315–1322. [PubMed]
- Fidler IJ, Gersten DM, Budmen MB. Characterization in vivo and in vitro of tumor cells selected for resistance to syngeneic lymphocyte-mediated cytotoxicity. Cancer Res. 1976 Sep;36(9 PT.1):3160–3165. [PubMed]
- Knisely TL, Niederkorn JY. Immunologic evaluation of spontaneous regression of an intraocular murine melanoma. Invest Ophthalmol Vis Sci. 1990 Feb;31(2):247–257. [PubMed]
- Niederkorn JY. T cell subsets involved in the rejection of metastases arising from intraocular melanomas in mice. Invest Ophthalmol Vis Sci. 1987 Aug;28(8):1397–1403. [PubMed]
- Niederkorn JY. Suppressed cellular immunity in mice harboring intraocular melanomas. Invest Ophthalmol Vis Sci. 1984 Apr;25(4):447–454. [PubMed]
- Sanborn GE, Nguyen P, Gamel J, Niederkorn JY, Ngyuen P. Reduction of enucleation-induced metastasis in intraocular melanoma by periorbital irradiation. Arch Ophthalmol. 1987 Sep;105(9):1260–1264. [PubMed]
- Niederkorn JY, Sanborn GE, Gamel JW. Suicide enzyme inhibition as a chemotherapeutic strategy for controlling metastases derived from intraocular melanomas. Invest Ophthalmol Vis Sci. 1987 Nov;28(11):1844–1850. [PubMed]
- Niederkorn JY, Knisely TL, Mayhew E. Immune rejection of metastases arising from intraocular tumors in mice. Invest Ophthalmol Vis Sci. 1986 Sep;27(9):1355–1361. [PubMed]
- Niederkorn JY. Enucleation in consort with immunologic impairment promotes metastasis of intraocular melanomas in mice. Invest Ophthalmol Vis Sci. 1984 Sep;25(9):1080–1086. [PubMed]
- Grossniklaus HE, Barron BC, Wilson MW. Murine model of anterior and posterior ocular melanoma. Curr Eye Res. 1995 May;14(5):399–404. [PubMed]
- Grossniklaus HE, Wilson MW, Barron BC, Lynn MJ. Anterior vs posterior intraocular melanoma. Metastatic differences in a murine model. Arch Ophthalmol. 1996 Sep;114(9):1116–1120. [PubMed]
- Ma D, Luyten GP, Luider TM, Niederkorn JY. Relationship between natural killer cell susceptibility and metastasis of human uveal melanoma cells in a murine model. Invest Ophthalmol Vis Sci. 1995 Feb;36(2):435–441. [PubMed]
- Ma D, Luyten GP, Luider TM, Jager MJ, Niederkorn JY. Association between NM23-H1 gene expression and metastasis of human uveal melanoma in an animal model. Invest Ophthalmol Vis Sci. 1996 Oct;37(11):2293–2301. [PubMed]
- Lambrou FH, Chilbert M, Mieler WF, Williams GA, Olsen K. A new technique for subchoroidal implantation of experimental malignant melanoma. Invest Ophthalmol Vis Sci. 1988 Jun;29(6):995–998. [PubMed]
- Hu LK, Huh K, Gragoudas ES, Young LH. Establishment of pigmented choroidal melanomas in a rabbit model. Retina. 1994;14(3):264–269. [PubMed]
- Tanaka S, Yamamoto H, Takeuchi S, Takeuchi T. Melanization in albino mice transformed by introducing cloned mouse tyrosinase gene. Development. 1990 Feb;108(2):223–227. [PubMed]
- Bradl M, Klein-Szanto A, Porter S, Mintz B. Malignant melanoma in transgenic mice. Proc Natl Acad Sci U S A. 1991 Jan 1;88(1):164–168. [PubMed]
- Anand R, Ma D, Alizadeh H, Comerford SA, Sambrook JF, Gething MJ, McLean IW, Niederkorn JY. Characterization of intraocular tumors arising in transgenic mice. Invest Ophthalmol Vis Sci. 1994 Aug;35(9):3533–3539. [PubMed]
- Ma D, Niederkorn JY. Efficacy of tumor-infiltrating lymphocytes in the treatment of hepatic metastases arising from transgenic intraocular tumors in mice. Invest Ophthalmol Vis Sci. 1995 May;36(6):1067–1075. [PubMed]
- Ma D, Alizadeh H, Comerford SA, Gething MJ, Sambrook JF, Anand R, Niederkorn JY. Rejection of intraocular tumors from transgenic mice by tumor-infiltrating lymphocytes. Curr Eye Res. 1994 May;13(5):361–369. [PubMed]
- Powell MB, Hyman P, Bell OD, Balmain A, Brown K, Alberts D, Bowden GT. Hyperpigmentation and melanocytic hyperplasia in transgenic mice expressing the human T24 Ha-ras gene regulated by a mouse tyrosinase promoter. Mol Carcinog. 1995 Feb;12(2):82–90. [PubMed]
- Richerson JT, Burns RP, Misfeldt ML. Association of uveal melanocyte destruction in melanoma-bearing swine with large granular lymphocyte cells. Invest Ophthalmol Vis Sci. 1989 Dec;30(12):2455–2460. [PubMed]
- Fidler IJ. Selection of successive tumour lines for metastasis. Nat New Biol. 1973 Apr 4;242(118):148–149. [PubMed]
- Char DH. History of ocular oncology. Ophthalmology. 1996 Aug;103(8 Suppl):S96–101. [PubMed]
- Char DH, Castro JR, Quivey JM, Chen GT, Lyman JT, Stone RD, Irvine AR, Barricks M, Crawford JB, Hilton GF, Lonn LI, Schwartz A. Helium ion charged particle therapy for choroidal melanoma. Ophthalmology. 1980 Jun;87(6):565–570. [PubMed]
- Gragoudas ES, Goitein M, Verhey L, Munzenreider J, Suit HD, Koehler A. Proton beam irradiation. An alternative to enucleation for intraocular melanomas. Ophthalmology. 1980 Jun;87(6):571–581. [PubMed]
- Shields JA, Shields CL, Donoso LA. Management of posterior uveal melanoma. Surv Ophthalmol. 1991 Nov–Dec;36(3):161–195. [PubMed]
- Lommatzsch PK. Results after beta-irradiation (106Ru/106Rh) of choroidal melanomas: 20 years' experience. Br J Ophthalmol. 1986 Nov;70(11):844–851. [PubMed]
- Shields JA, Augsburger JJ, Brady LW, Day JL. Cobalt plaque therapy of posterior uveal melanomas. Ophthalmology. 1982 Oct;89(10):1201–1207. [PubMed]
- MEYER-SCHWICKERATH G. The preservation of vision by treatment of intraocular tumors with light coagulation. Arch Ophthalmol. 1961 Oct;66:458–466. [PubMed]
- Shields JA, Glazer LC, Mieler WF, Shields CL, Gottlieb MS. Comparison of xenon arc and argon laser photocoagulation in the treatment of choroidal melanomas. Am J Ophthalmol. 1990 Jun 15;109(6):647–655. [PubMed]
- Oosterhuis JA, Journée-de Korver HG, Kakebeeke-Kemme HM, Bleeker JC. Transpupillary thermotherapy in choroidal melanomas. Arch Ophthalmol. 1995 Mar;113(3):315–321. [PubMed]
- Journée-de Korver JG, Oosterhuis JA, Kakebeeke-Kemme HM, de Wolff-Rouendaal D. Transpupillary thermotherapy (TTT) by infrared irradiation of choroidal melanoma. Doc Ophthalmol. 1992;82(3):185–191. [PubMed]
- Journée-de Korver JG, Oosterhuis JA, van Best JA, Fakkel J. Xenon arch photocoagulator used for transpupillary hyperthermia. Doc Ophthalmol. 1991;78(3-4):183–187. [PubMed]
- Shields CL, Shields JA, DePotter P, Kheterpal S. Transpupillary thermotherapy in the management of choroidal melanoma. Ophthalmology. 1996 Oct;103(10):1642–1650. [PubMed]
- Nuijs-Beems EM, Oosterhuis JA, Verburg-van der Marel EH, de Wolff-Rouendaal D, van Delft JL, van Best JA. Tumor destruction by intermediate level hyperthermia. Curr Eye Res. 1990 Aug;9(8):771–780. [PubMed]
- Fine SL. No one knows the preferred management for choroidal melanoma. Am J Ophthalmol. 1996 Jul;122(1):106–108. [PubMed]
- Shields CL, Shields JA, Kiratli H, De Potter P, Cater JR. Risk factors for growth and metastasis of small choroidal melanocytic lesions. Ophthalmology. 1995 Sep;102(9):1351–1361. [PubMed]
- Specht CS, McLean IW, Biscoe BW. Traumatic enucleation for posterior uveal melanoma. Am J Ophthalmol. 1990 Nov 15;110(5):518–521. [PubMed]
- DUNN TB. Normal and pathologic anatomy of the reticular tissue in laboratory mice, with a classification and discussion of neoplasms. J Natl Cancer Inst. 1954 Jun;14(6):1281–1433. [PubMed]
- Park SS, Li L, Korn TS, Mitra MM, Niederkorn JY. Effect of transforming growth factor-beta on plasminogen activator production of cultured human uveal melanoma cells. Curr Eye Res. 1996 Jul;15(7):755–763. [PubMed]
- O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, Folkman J. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell. 1994 Oct 21;79(2):315–328. [PubMed]
- Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995 Jan;1(1):27–31. [PubMed]
- Hendrix MJ, Seftor EA, Seftor RE, Kirschmann DA, Gardner LM, Boldt HC, Meyer M, Pe'er J, Folberg R. Regulation of uveal melanoma interconverted phenotype by hepatocyte growth factor/scatter factor (HGF/SF). Am J Pathol. 1998 Apr;152(4):855–863. [PubMed]
|